D Hashad1, A Sorour, A Ghazal, I Talaat. 1. Clinical Pathology Department, Faculty of Medicine, Alexandria University, Azarita, Alexandria, Egypt. doaa_hashad2003@yahoo.com
Abstract
BACKGROUND: Cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cfDNA and prognostic parameters. METHODS: Plasma samples were obtained from 99 subjects; 42 with breast cancer (BC), 30 with benign breast lesions, and 27 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified using a real-time quantitative PCR method. Immunohistochemistry was done on formalin-fixed paraffin-embedded sections to evaluate the status of hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), and the protein expression of both Her2/neu and Topoisomerase IIα. RESULTS: The level of cfDNA in the BC group was significantly higher than in the benign lesions and control groups. cfDNA level was associated with malignant tumor size, lymph node involvement, stage, and grade as well as Her2/neu and Topoisomerase IIα expression, while it was not associated with ER or PR status. CONCLUSIONS: The present study suggests that the level of cfDNA can be easily quantified using plasma samples. Thus, level of plasma cfDNA might constitute an important noninvasive diagnostic and prognostic valuable tool in cancer breast patients' management.
BACKGROUND: Cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cfDNA and prognostic parameters. METHODS: Plasma samples were obtained from 99 subjects; 42 with breast cancer (BC), 30 with benign breast lesions, and 27 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified using a real-time quantitative PCR method. Immunohistochemistry was done on formalin-fixed paraffin-embedded sections to evaluate the status of hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), and the protein expression of both Her2/neu and Topoisomerase IIα. RESULTS: The level of cfDNA in the BC group was significantly higher than in the benign lesions and control groups. cfDNA level was associated with malignant tumor size, lymph node involvement, stage, and grade as well as Her2/neu and Topoisomerase IIα expression, while it was not associated with ER or PR status. CONCLUSIONS: The present study suggests that the level of cfDNA can be easily quantified using plasma samples. Thus, level of plasma cfDNA might constitute an important noninvasive diagnostic and prognostic valuable tool in cancer breast patients' management.
Authors: Raquel Catarino; Maria M Ferreira; Helena Rodrigues; Ana Coelho; Ana Nogal; Abreu Sousa; Rui Medeiros Journal: DNA Cell Biol Date: 2008-08 Impact factor: 3.311
Authors: M I Sandri; D Hochhauser; P Ayton; R C Camplejohn; R Whitehouse; H Turley; K Gatter; I D Hickson; A L Harris Journal: Br J Cancer Date: 1996-06 Impact factor: 7.640
Authors: J Hannemann; P Kristel; H van Tinteren; M Bontenbal; Q G C M van Hoesel; W M Smit; M A Nooij; E E Voest; E van der Wall; P Hupperets; E G E de Vries; S Rodenhuis; M J van de Vijver Journal: Br J Cancer Date: 2006-10-31 Impact factor: 7.640
Authors: Corina Kohler; Ramin Radpour; Zeinab Barekati; Reza Asadollahi; Johannes Bitzer; Edward Wight; Nicole Bürki; Claude Diesch; Wolfgang Holzgreve; Xiao Yan Zhong Journal: Mol Cancer Date: 2009-11-17 Impact factor: 27.401
Authors: Zhong Ye; Chun Wang; Shaogui Wan; Zhaomei Mu; Zhenchao Zhang; Maysa M Abu-Khalaf; Frederick M Fellin; Daniel P Silver; Manish Neupane; Rebecca J Jaslow; Saveri Bhattacharya; Theodore N Tsangaris; Inna Chervoneva; Adam Berger; Laura Austin; Juan P Palazzo; Ronald E Myers; Neha Pancholy; Darayus Toorkey; Kaelan Yao; Max Krall; Xiuling Li; Xiaobing Chen; Xiuhong Fu; Jinliang Xing; Lifang Hou; Qiang Wei; Bingshan Li; Massimo Cristofanilli; Hushan Yang Journal: Eur J Cancer Date: 2018-12-04 Impact factor: 9.162